Acinetobacter spp.: Multidrug-Resistant Pathogens in ICU Settings

02 Mar

Acinetobacter spp.: Multidrug-Resistant Pathogens in ICU Settings

Environmental persistence, hospital transmission, and the clinical challenge of multidrug resistance

In modern hospital wards, particularly in intensive care units, a group of Gram-negative bacilli has emerged as one of the most challenging threats to global healthcare-associated infection control due to extraordinary environmental persistence and rapidly escalating antimicrobial resistance.

These organisms rarely cause disease in healthy individuals, but preferentially infect critically ill patients with compromised host defenses. Their most clinically significant representatives are frequently classified as multidrug-resistant superbugs. This group is collectively referred to as Acinetobacter spp.

I. Taxonomic Position and Fundamental Characteristics

Acinetobacter spp. are taxonomically classified within the phylum Proteobacteria, class Gammaproteobacteria, order Pseudomonadales, and family Moraxellaceae. The genus comprises multiple species, among which Acinetobacter baumannii is of greatest clinical relevance.

Members of this genus are Gram-negative coccobacilli that often appear in pairs under light microscopy, occasionally resembling diplococci. A defining morphological feature is the absence of flagella, resulting in minimal or absent motility, which is reflected in the genus name. They are obligate aerobic, non-fermentative chemoheterotrophs.

The most remarkable biological characteristic of Acinetobacter spp. is their exceptional environmental adaptability and survival capacity. These organisms can persist for weeks to months on dry inanimate surfaces such as medical equipment, bedside furniture, and curtains. They tolerate nutrient-poor conditions and exhibit partial resistance to commonly used disinfectants.

This pronounced ability to survive under desiccated conditions constitutes the biological foundation for long-term colonization and sustained transmission within hospital environments.

II. Epidemiology and Clinical Pathogenicity

Acinetobacter spp. are widely distributed in nature and can be isolated from soil and water. In healthcare settings, however, they function primarily as opportunistic pathogens and are a major cause of hospital-acquired infections.

Transmission Routes and High-Risk Environments

Transmission occurs predominantly via contact. The hands of healthcare workers, contaminated medical devices such as ventilator circuits and monitoring probes, and the immediate patient environment serve as primary reservoirs. Intensive care units, burn units, and neurosurgical wards represent high-incidence settings due to extensive use of invasive devices and broad-spectrum antibiotics.

High-Risk Populations

Patients with prolonged hospitalization, particularly in intensive care units
Individuals undergoing major surgery or experiencing severe trauma
Immunocompromised patients
Neonates
Patients with antibiotic-induced microbiota disruption

Major Infection Types

Ventilator-associated pneumonia: The most frequent and severe manifestation, closely linked to mechanical ventilation
Bloodstream infections: Often secondary to central venous catheterization
Surgical site and wound infections: Including postoperative and burn wound infections
Urinary tract infections: Typically associated with indwelling urinary catheters
Central nervous system infections: Observed in post-neurosurgical or traumatic brain injury patients

III. The Severe Challenge of Multidrug Resistance

The most critical clinical concern associated with Acinetobacter spp., particularly Acinetobacter baumannii, is the rapid evolution and dissemination of multidrug-resistant, extensively drug-resistant, and in some cases pan-drug-resistant phenotypes.

Complex Resistance Mechanisms

Production of antibiotic-inactivating enzymes: Acquisition and expression of multiple beta-lactamases, including carbapenem-hydrolyzing enzymes such as OXA-type carbapenemases and NDM, leading to failure of last-line antibiotics
Alteration of antimicrobial targets: Mutations in DNA gyrase and topoisomerase IV conferring fluoroquinolone resistance
Reduced membrane permeability and efflux pump overexpression: Limiting intracellular antibiotic accumulation
Biofilm formation: Development of biofilms on medical devices and tissues, markedly enhancing resistance to antibiotics and host immune defenses

Therapeutic options for extensively resistant strains are extremely limited. Remaining active agents may include polymyxins, tigecycline, and a small number of newer antimicrobials. Combination therapy is frequently employed, although efficacy is variable and nephrotoxicity and other adverse effects remain significant concerns.

IV. Diagnostic Approaches and Infection Control Strategies

Diagnosis

Diagnosis relies on isolation and identification from clinical specimens such as blood, respiratory secretions, cerebrospinal fluid, and wound exudates. Matrix-assisted laser desorption ionization–time of flight mass spectrometry enables rapid and accurate species-level identification.

Molecular diagnostic methods, including PCR-based detection of resistance-associated genes, provide valuable support for early confirmation of resistance profiles and optimization of initial antimicrobial therapy.

Infection Prevention and Control Strategies

Given the limited therapeutic options, prevention of transmission is substantially more effective than treatment of established infection. Comprehensive infection prevention and control measures are essential.

Contact precautions: Immediate implementation of single-room isolation or cohorting for colonized or infected patients
Hand hygiene and environmental decontamination: Strict adherence to hand hygiene protocols and enhanced disinfection of high-touch surfaces
Antimicrobial stewardship: Rational antibiotic use with restriction of unnecessary carbapenem and broad-spectrum antibiotic exposure
Device and catheter management: Strict aseptic technique and prompt removal of unnecessary invasive devices
Active surveillance: Targeted screening of high-risk units during outbreak situations to identify colonized patients early